A 39-year-old female patient who had been receiving 30 mg of baclofen daily for 5 months was admitted to the hospital about 12 hr after an overdose of this drug (450 mg). On admission, she was comatose, flaccid, and in respiratory failure. Later she developed muscle twitchings and had several epileptic fits. She was treated symptomatically and became conscious within 36 hr. However, approximately 65 hr after the overdose she developed sinus tachycardia which was successfully treated with oral propranolol. Plasma concentrations, as measured on days 2 and 3, were within the therapeutic range but the elimination half-life was prolonged.
Introduction
Baclofen is a derivative of a naturally occurring y-aminobutyric acid (GABA) (Faigle and Keberle, 1972) and is used for the treatment of muscle spasticity (Paeslack, 1972) . It exerts a long-lasting attenuating effect on muscle tone and, in the recommended therapeutic dosage, predominantly acts at the spinal level (Koella, 1972) . Side effects are occasional and usually restricted to sedation, diarrhoea and confusional states (Paeslack, 1972) . GABA is considered to be an inhibitory neurotransmitter and massive overdose with baclofen has been reported as being associated with impaired consciousness, respiratory depression, muscle weakness, involuntary jerking movements and epileptic convulsions (Paeslack, 1972; Paulson, 1976 It will be seen that although the plasma concentration of baclofen at 36 hr was within the therapeutic range, the rate of fall was rather slow and there was a secondary peak. Plasma elimination half-life of baclofen in this patient was much longer (34.6 hr) than that observed following therapeutic dosage (40mg/day, 3-4hr) (Faigle and Keberle, 1972) .
Discussion
Baclofen crosses the blood brain barrier poorly (Faigle and Keberle, 1972) , and in the recommended therapeutic dosage its central effect is almost negligible. However, massive overdosage is characterized by central depression as observed in this patient and reported previously (Paulson, 1976 (Paulson, 1976; Ciba Labs, Horsham, personal communication, 1979) , to control epileptic convulsions, probably contributed further to the duration of unconsciousness.
Despite this drawback and in view of the associated severe respiratory depression, diazepam or clonazepam remain the treatment of choice to control epileptic convulsions. There was no evidence of increased salivation or increased cholinergic activity in this patient, as suggested by Paeslack (1972) .
Plasma concentrations of baclofen in this patient, as estimated on days 2 and 3 were all within therapeutic range. It is difficult to explain the rise in baclofen concentration on the 3rd day which has also been observed by other investigators. This may have been due to a change in the volume of distribution of the drug, or to a significant amount of the drug being recycled via the entero-hepatic system. In this patient, elimination half-life (34-5 hr) appeared to be much longer than was observed in healthy subjects following a single oral dose (4 hr). It (Ghose, 1980) , although this drug's half-life during steady state was reported to be 36-40 hr following 2 weeks' medication (Braithwaite and Widdop, 1971 (Paulson, 1976 
